August 9, 2021 — Boston Scientific is recalling INGENIO family of pacemakers and CRT-Ps due to the risk of incorrect transition to safety mode. Safety mode is intended to provide backup if the device is faulty. However, in safety mode, there is a risk of inappropriate loss of pacing due to sensing of muscle contractions. If the device incorrectly goes into safety mode, the device cannot be reprogrammed and must be replaced.

August 5, 2021 —  A prospective, non-randomized, multicenter, first-in-human clinical study found good diagnostic and procedural guidance value using a new 3D/4D intracardiac echo (ICE) imaging catheter in radio frequency and cryo-ablation procedures, and left atrial appendage (LAA) occlusion procedures.

August 5, 2021 — The U.S. Food and Drug Administration (FDA) has cleared clearance Abbott's latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software.

August 3, 2021 — A subgroup analysis of the EAST – AFNET 4 study population revealed early initiation of rhythm control therapy is associated with clinical benefit in patients with heart failure and recently diagnosed atrial fibrillation (AF). The new findings were presented by Dr. Andreas Rillig, University Heart Center Hamburg, Germany, at the Heart Rhythm Society (HRS) annual meeting. 

August 4, 2021 — Temporary Spinal cord stimulation (SCS) was effective in suppressing post-operative atrial fibrillation (AF) after coronary artery bypass (CAGB) surgery CABG without any adverse events in a randomized pilot study.

August 3, 2021 – Results from a new clinical trial show an increased risk of cardiac events, like sudden cardiac death (SCD), among women with congenital long QT syndrome (LQTS) who are taking progestin-only oral contraceptives (OC) without beta-blocker therapy. The trial is the first to assess the association of OCs by formulation type on the risk of cardiac events in female patients with congenital LQTS.

August 3, 2021 – A recent study unveiled a novel sinus node ablation technique that provides a safe and effective treatment option for patients suffering from symptomatic, drug-resistant inappropriate sinus tachycardia (IST). Results of the Susruta-IST Registry were presented as a late-breaking clinical trial at Heart Rhythm 2021, the annual meeting of the Heart Rhythm Society (HRS).

August 3, 2021 – A new analysis of the Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial examines cost-effectiveness of catheter ablation compared to drug therapy. CABANA is the largest trial comparing catheter ablation to drug therapy and this is first analysis on costs and cost effectiveness of ablation using patient-level data.

August 3, 2021 – Biosense Webster, the global leader in cardiac arrhythmia treatment and part of Johnson & Johnson Medical Devices Companies, announced today that data from 16 company sponsored studies will be presented at Heart Rhythm 2021, the Heart Rhythm Society (HRS) annual meeting. The data presented reflects Biosense Webster’s continued innovation and commitment to advancing science in the field of electrophysiology with the goal of improving patient outcomes.

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO-AffectDX trial, designed to evaluate clinical outcomes of cardiac resynchronization therapy (CRT) in patients with heart failure (HF) and atrial fibrillation (AF).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now